Stay updated on EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:10:41.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the response rate of the combination therapy involving pembrolizumab and recombinant EphB4-HSA fusion protein for treating patients with non-small cell lung cancer or head and neck squamous cell cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:03.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. Additionally, detailed eligibility criteria for the study have been included.
    Difference
    52%
    Check dated 2024-05-22T21:20:57.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:24:54.000Z thumbnail image

Stay in the know with updates to EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial page.